Research programme: vaccines - Allergy Therapeutics
Latest Information Update: 25 Sep 2020
At a glance
- Originator Allergy Therapeutics
- Class Antiasthmatics; Antineoplastics; Antipsoriatics; Skin disorder therapies; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Asthma; Atopic dermatitis; Psoriasis; Solid tumours
Most Recent Events
- 03 Sep 2020 Allergy Therapeutics in-licenses virus-like particle technology from Saiba AG and DeepVax GmbH
- 03 Sep 2020 Vaccines - Allergy Therapeutics is available for licensing as of 03 Sep 2020. https://www.allergytherapeutics.com/
- 03 Sep 2020 Early research in Asthma in United Kingdom (Parenteral)